J P Morgan Chase & Co cut shares of Genomic Health (NASDAQ:GHDX) from a neutral rating to an underweight rating in a research report released on Wednesday morning. J P Morgan Chase & Co currently has $25.00 target price on the medical research company’s stock.

GHDX has been the subject of several other research reports. Zacks Investment Research upgraded shares of Genomic Health from a sell rating to a hold rating in a research report on Friday, October 13th. Cowen restated a hold rating and issued a $34.00 price objective on shares of Genomic Health in a research report on Friday, September 1st. Canaccord Genuity reiterated a buy rating and set a $39.00 price target on shares of Genomic Health in a research report on Wednesday, November 15th. Jefferies Group reiterated a hold rating and set a $33.00 price target on shares of Genomic Health in a research report on Thursday, September 14th. Finally, BidaskClub upgraded shares of Genomic Health from a sell rating to a hold rating in a research report on Saturday, August 26th. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and one has given a buy rating to the company’s stock. Genomic Health presently has a consensus rating of Hold and an average target price of $31.57.

Genomic Health (GHDX) traded down $2.05 on Wednesday, reaching $28.00. 455,800 shares of the company’s stock traded hands, compared to its average volume of 118,663. Genomic Health has a 52-week low of $26.37 and a 52-week high of $34.02.

In other news, COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction that occurred on Tuesday, October 10th. The shares were sold at an average price of $31.93, for a total transaction of $159,650.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider James J. Vaughn sold 1,379 shares of Genomic Health stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $32.51, for a total transaction of $44,831.29. The disclosure for this sale can be found here. In the last quarter, insiders have sold 16,379 shares of company stock valued at $511,531. 46.20% of the stock is owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC bought a new position in Genomic Health during the 3rd quarter worth approximately $138,000. SG Americas Securities LLC boosted its stake in Genomic Health by 37.8% during the 2nd quarter. SG Americas Securities LLC now owns 6,122 shares of the medical research company’s stock worth $199,000 after acquiring an additional 1,679 shares during the last quarter. Legal & General Group Plc boosted its stake in Genomic Health by 11.4% during the 2nd quarter. Legal & General Group Plc now owns 6,932 shares of the medical research company’s stock worth $226,000 after acquiring an additional 710 shares during the last quarter. Jane Street Group LLC bought a new position in Genomic Health during the 3rd quarter worth approximately $227,000. Finally, Parametric Portfolio Associates LLC boosted its stake in Genomic Health by 5.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after acquiring an additional 441 shares during the last quarter. 89.76% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “Genomic Health (GHDX) Downgraded to Underweight at J P Morgan Chase & Co” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another publication, it was illegally copied and reposted in violation of US & international copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/14/genomic-health-ghdx-downgraded-to-underweight-at-j-p-morgan-chase-co.html.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Analyst Recommendations for Genomic Health (NASDAQ:GHDX)

Receive News & Stock Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related stocks with our FREE daily email newsletter.